Aerovate Therapeutics Inc

NASDAQ AVTE

Data sourced from iex and EODHD
Download Data

Aerovate Therapeutics Inc Income Statement 2020 - 2024

This table shows the Income Statement for Aerovate Therapeutics Inc going from 2020 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31
Revenue
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -
Cost of Revenue
M 0 0 0 0 0 0 - - - - - - - - - - -
Gross Profit
M 0 0 0 0 0 0 - - - - - - - - - - -
Operating Expenses
M 25 22 21 20 18 16 - - - - - - - - - - -
Selling, General, and Administrative Expenses (SG&A)
M 5 4 4 4 4 4 3 4 4 3 3 1 1 0 0 0 0
Research and Development (R&D) Expenses
M 20 18 17 16 13 12 11 8 7 5 3 4 2 3 2 1 1
Other Operating Expenses
M 0 0 0 0 0 0 - - - - - - - - - - -
Costs and Expenses
M 25 22 21 20 18 16 - - - - - - - - - - -
Operating Income
M -25 -22 -21 -20 -18 -16 -14 -12 -11 -8 -6 -6 -3 -4 -2 -2 -1
Interest Expense
M - 1 - 1 -1 1 1 0 0 0 0 0 0 - - - 0
Non-operating Income/Expense
M 1 2 2 0 1 1 1 0 0 0 0 0 0 0 0 -1 0
EBT
M -23 -20 -20 -19 -17 -15 -14 -12 -11 -8 -6 -6 -3 -4 -2 -2 -1
Income Tax Provision
M - 0 0 -1 -1 0 -1 0 0 0 - 0 0 -1 - - 0
Income after Tax
M - -20 -20 -18 -15 -15 -13 -12 -11 -8 - -6 -3 -3 - - -1
Non-Controlling Interest
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 -
Net Income
M - - - -19 -17 -15 -14 -12 -11 -8 -6 -6 -3 - -2 -2 -1
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 27,795,827.00 27,695,184.00 27,640,542.00 25,166,505.00 24,777,847.00 24,472,104.00 24,454,786.00 24,410,503.00 24,410,393.00 23,885,017.00 23,885,017.00 243,076.00 21,575,930.00 243,076.00 243,076.00 243,076.00 4,496,704.00
EBITDA
M -25 -22 -21 -20 -18 -16 -14 -12 -11 -8 -6 -6 -3 -4 -2 -2 -1
Depreciation and Amortization
M 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - 0
EBIT
M -25 -22 -21 -20 -18 -16 -14 -12 -11 -8 -6 -6 -3 -4 -2 -2 -1
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - -
Tax Rate (Effective)
% - -0.28 0.13 6.90 6.77 -0.17 4.15 1.87 1.00 -0.04 - 0.03 0.04 17.65 - - -2.65
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 - 0 0 0
Gross Profit Margin
% - 79.41 - - - - - - - - - - - - - - -
Operating Income Margin
% - -16,225.00 - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -16,204.41 - - - - - - - - - - - - - - -
EBIT Ratio
% - -16,225.00 - - - - - - - - - - - - - - -
EBT Ratio
% - -14,968.38 - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email